Daniel H. Solomon, MD, MPH, & Andrew Concoff, MD, FACR |
Guest columnists Dr. Daniel Solomon & Dr. Andrew Concoff discuss the potential of technology, such as mobile health apps, to enhance remote care & improve access for underserved patients.
The Year in Review session during ACR Convergence 2020 will address advances in clinical and basic science related to rheumatology, including drug safety, precision medicine, the COVID-19 pandemic and more.
I have always been dissatisfied with the apparent dichotomy between researchers and clinicians; this is a false divide. Yes, research includes laboratory-based investigation, clinical trials, and retrospective and prospective studies of disease entities, among other pursuits. However, clinicians also contribute to research by sharing clinical data and through observations of their patients. Clinicians’ daily contributions…
SNOWMASS VILLAGE, COLO.—Choosing the right treatment at the right time is the brass ring all rheumatologists hope for. Precision medicine provides the ability to leverage clinical, biomarker and omics data to predict and personalize future treatment for rheumatoid arthritis (RA). “New data and new methods to analyze the data are helping us better predict patterns…
ATLANTA—The increasing ease and the lowering cost of genome and exome sequencing make discovery and diagnosis of rare diseases more feasible than ever, but hurdles still need to be cleared before the world of medicine can fully harness the power of this information boom, experts said in a session at the 2019 ACR/ARP Annual Meeting….
ATLANTA—When it comes to treating rheumatoid arthritis (RA) patients, most clinicians agree: One size does not fit all. Many treatment options exist, and seldom is there 100% consensus on what the first course of action or general approach should be. In the face of such variability, four clinicians took the stage at the 2019 ACR/ARP…
Precision medicine is a hot topic, but what does it mean for clinical practice in rheumatology? This year’s Annual Meeting ARP Pre-Meeting Course will explore precision medicine’s implications for biomarkers, pharmacogenomics, psychosocial aspects of care and more…
CHICAGO—The world of rheumatology is beginning to harness the promise of the microbiome, with evidence showing components of the gut may help predict response to medication and may be manipulated to improve how well a treatment works, said Jose Scher, MD, at the 2019 ACR State-of-the-Art Clinical Symposium, held April 5–7. “We can truly exploit…
A recent proof-of-concept study to evaluate nuclear imaging in interstitial lung disease (ILD) concludes it is feasible to study ILD subtypes using this technology to visualize specific molecular processes of ILD. The process has important potential applications for the development of targeted molecular therapies.1 ILD is an umbrella term for a group of heterogeneous lung…